Clonal Heterogeneity in Urothelial Cancer
Bishoy Faltas, MD, clinical fellow, Weill Cornell Medical College, discusses clonal heterogeneity in platinum-resistant metastatic urothelial cancer.
Clinical Pearls
Bishoy Faltas, MD, clinical fellow, Weill Cornell Medical College, discussesclonal heterogeneity in platinum-resistant metastatic urothelial cancer.
- This study found a significant degree of both inter- and intra-patient heterogeneity.
- There were differences in the patterns of evolution of molecular alterations in these samples.
- Subclonal mutations went on to be enriched in and constitute most mutations in metastatic samples.
- Mutations in primary samples were identified that were not enriched in metastatic samples.
- It was found that the metastatic samples continued to change even after evolving from the primary tumor samples.
DREAMM-8 Trial Demonstrates Benefits of Belantamab Mafodotin
October 3rd 2024Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.
Read More
Single CAR-T Infusion Shows Deep and Durable Responses in Relapsed Myeloma
October 2nd 2024A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.
Read More
